Guided TherapeuticsGTHP -12.50%18 PS Ratio is 23.33 as of Jul. 01, 2026, which is 65% below its 10-year median of 67.00. GuruFocus rates GTHP with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Guided Therapeutics ranks worse than 92.8% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Guided Therapeutics's share price is $0.21.
Guided Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, Guided Therapeutics's PS Ratio for today is 23.33.
The historical rank and industry rank for Guided Therapeutics's PS Ratio or its related term are showing as below:
GTHP'
s PS Ratio Range Over the Past 10 Years
Min: 0.06 Med: 67 Max: 303.33
Current: 23.34
During the past 13 years, Guided Therapeutics's highest PS Ratio was 303.33. The lowest was 0.06. And the median was 67.00.
GTHP's PS Ratio is ranked worse than 92.8% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs GTHP: 23.34
During the past 13 years, Guided Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 81.70% per year. The lowest was -97.40% per year. And the median was -66.00% per year.
Back to Basics: PS Ratio
Guided Therapeutics (OTCPK:GTHP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Guided Therapeutics PS Ratio Related Terms
Guided Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Guided Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Guided Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guided Therapeutics PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Guided Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Guided Therapeutics's Share Price of today is $0.21. Guided Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Guided Therapeutics (GTHP) has a PS Ratio of 23.33 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Guided Therapeutics and its competitors. This is 65% below median its historical median of 67.00. Over the past decade, Guided Therapeutics' PS Ratio has ranged from 0.06 to 303.33. According to the industry distribution chart, Guided Therapeutics ranks #747 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 92.8%.
Is Guided Therapeutics' PS Ratio too high?
Guided Therapeutics' current PS Ratio of 23.33 is 65% below median its 10-year median of 67.00. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 303.33. The Medical Devices & Instruments industry median PS Ratio is 2.94. Guided Therapeutics' value of 23.33 is 693.5% above this industry median. Based on the distribution chart, Guided Therapeutics ranks #747 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Guided Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' PS Ratio compare to CTSO and IRIX?
According to the Medical Devices & Instruments industry distribution chart, Guided Therapeutics ranks #747 out of 805 companies for PS Ratio. This places Guided Therapeutics in the lower half of its industry. The industry median PS Ratio is 2.94. Guided Therapeutics' value of 23.33 is 693.5% above this benchmark. Historically, Guided Therapeutics' own PS Ratio has ranged from 0.06 to 303.33 over the past decade. While the company's 10-year median is 67.00 vs. the industry median of 2.94, Guided Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guided Therapeutics's current PS Ratio of 23.33 is 693.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Guided Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guided Therapeutics's current PS Ratio is 23.33, which is 65% below median its own 10-year median of 67.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current PS Ratio of 23.33. The current PS Ratio is 23.33, which is 65% below median its 10-year median of 67.00 and 693.5% above the Medical Devices & Instruments industry median of 2.94. Guided Therapeutics' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current PS Ratio is 23.33 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
18GF Score
Get the complete analysis for GTHP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GTHP has been successfully added to your 
